ONCOVITA, a biotechnology company specializing in the development of innovative vaccines and a spin-off from the Institut Pasteur, and UNITHER Pharmaceuticals, a world leader in the manufacture of sterile single-dose vaccines, announce their strategic partnership for the development and production of a new combined prophylactic vaccine for the prevention of infectious diseases in children..

November 2022, during Emmanuel Macron's official visit to Amiens, the President of the Republic announced an important strategic project for Unither Pharmaceuticals. Eric Goupil, CEO of Unither Pharmaceutical to present the launch of the "Euroject®" project for filling ready-to-use single-dose vaccines using Blow-Fill-Seal technology.

Recent innovations such as Euroject®, have opened up the possibility of using Blow-Fill-Seal (BFS) technology to design aseptic packaging systems that combine the efficiency of large-scale production with the highest guarantee of sterility. The result is a new type of pre-filled injectable device, in single dose, that can be mass-produced using a high-speed rotary machine at very low production costs. This new injectable form, due to a lower mass and volume than conventional injectable forms, offers greater ease of transport and storage conditions for products subject to a cold chain.

Transport is facilitated in many low- and middle-income countries where investments in cold chain infrastructure are inadequate. This new parenteral form can contribute to greater equity in access to new vaccines and ensure safe administration of vaccines, while being simple and cost-effective. This parenteral form also helps reduce the risk of breakage of glass vials. Products entering the cold chain can deteriorate due to loss of sealing of the caps or the elastomer pistons of the syringes, which can move or deform due to pressure changes during air transport. The single-dose presentation also allows for a reduction in the loss of unused products.

Launched in April 2023, construction work on a new 6,000 square meter building for the production of EuroJect® vaccine doses at Unither's site in Amiens will welcome its first production line in spring 2025. Unither has invested €90 million in the Euroject project, of which €34.8 million is financed by the French government. This new building will house three production lines for single-dose vaccine needles before the end of 2025. Three additional lines could be installed once Unither secures the necessary contracts to launch production. The building will ultimately produce more than one billion injectable doses per year.

In March 2025, Oncovita, a biotechnology company specializing in the development of innovative vaccines and a spin-off from the Institut Pasteur, and UNITHER Pharmaceuticals announced a strategic partnership for the development and production of a new combined prophylactic vaccine for the prevention of infectious diseases in children.

Oncovita, a winner of the "Innovations in Biotherapies and Bioproduction" program of the Innovation Santé France 2030 plan, is working on the design and early development of new therapeutic and prophylactic vaccines to combat various types of cancers and infectious diseases. Its vaccine candidates are developed using an innovative proprietary technological platform, Measovir®, which modifies the genome of the measles vaccine virus. This collaboration combines Measovir®, ONCOVITA's technology platform for developing highly immunogenic vaccines, with Euroject®, UNITHER Pharmaceuticals' Blow-Fill-Seal (BFS)-based device designed for the direct single-dose injection of vaccines and biological products. Together, these technologies aim to offer an efficient, cost-effective, and accessible solution suitable for large-scale production.

"We are convinced that the combination of Measovir® technology and the Euroject® device represents a major step forward in making vaccination simpler, safer, and more effective on a large scale. By facilitating vaccine administration and optimizing their accessibility, we are helping to improve and simplify patients' lives and address the major public health challenges of today and tomorrow," said Eric Goupil, President of Unither Pharmaceuticals.